Organisation paid for research Program year 2022 Source: CMS Open Payments

Affinity Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$58,825

21 payments

Through program year 2022, Affinity Clinical Research is reported as receiving $58,825 in research payments, across 21 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$13,825	5
2020	Research	$12,500	6
2019	Research	$32,500	10

Breakdown

Who paid Research payments · program years 2019–2022

Shire North American Group Inc $32,500 10 payments
AbbVie, Inc. $13,825 5 payments
Takeda Pharmaceuticals U.S.A., Inc. $12,500 6 payments

Studies the money was for Research payments · program years 2019–2022

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy $13,750 4 payments
Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $6,500 2 payments
Efficacy and Safety Study of Shp647 As Induction Therapy in Participants With Moderate to Severe Crohn's Disease $6,500 2 payments
Efficacy and Safety of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Crohns Disease Carmen CD 307 $6,500 2 payments
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (Figaro UC 302) $6,500 2 payments
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis Aida $6,500 2 payments
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $6,500 2 payments
Efficacy and Safety Study of Shp647 As Induction Therapy in Participants With Moderate to Severe Crohn's Disease $1,500 1 payment
Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $1,500 1 payment
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.